An independent two-stage DCF analysis by a frontier AI model.
The Cooper Companies operates what is essentially a highly lucrative annuity business. Once an optometrist fits a patient with a CooperVision lens, that patient rarely switches brands, resulting in years of highly predictable, recurring revenue. The contact lens market operates as a stable oligopoly with high barriers to entry, protecting incumbents from disruptive new entrants. Furthermore, structural shifts—such as consumers upgrading to daily disposables and the rising global need for myopia management in children—provide a long, clear runway for organic growth and margin expansion.
At current levels, the market accurately recognizes the quality and stability of COO's earnings. The stock trades near its calculated intrinsic value, representing a fair price for a wonderful, defensive business. While it may not offer a deep margin of safety for value investors seeking a bargain, its resilience to economic downturns and consistent compounding characteristics make it a robust holding for long-term capital preservation and steady growth.
A 7% free cash flow growth rate reflects the highly stable, recurring nature of the contact lens business. Growth is underpinned by the ongoing shift towards higher-margin daily disposable lenses and the emerging category of myopia management, supplemented by steady growth in the surgical division.
An 8.0% discount rate is appropriate for a company operating in a defensive, non-discretionary healthcare sector. The reliable, annuity-like revenue streams from contact lens wearers significantly lower the risk profile of the cash flows.
A 2.5% terminal growth rate aligns with long-term macroeconomic expectations. As an established player in an oligopoly, COO is expected to grow alongside the general economy and global demographic trends (such as an aging population) in perpetuity.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 1.5% | $81.28 | $66.50 | $56.27 | $48.77 | $43.03 |
| 2.0% | $91.44 | $73.15 | $60.96 | $52.25 | $45.72 |
| 2.5% | $104.50 | $81.28 | $66.50 | $56.27 | $48.77 |
| 3.0% | $121.92 | $91.44 | $73.15 | $60.96 | $52.25 |
| 3.5% | $146.30 | $104.50 | $81.28 | $66.50 | $56.27 |
■ Undervalued vs current price ■ Overvalued vs current price
Contact lenses are a medical device prescribed by an eye care professional. Because changing brands can affect fit and comfort, patients are highly reluctant to switch once they find a lens that works. This results in consumers purchasing the same product repeatedly, creating a predictable, annuity-like revenue stream.
Myopia (nearsightedness) is growing globally. Myopia management involves using specialized lenses, like COO's MiSight, to slow the progression of the condition in children, rather than just correcting their vision. This is a massive, largely untapped market that represents a significant growth vector for the company.
While CooperVision (contact lenses) is the primary revenue driver, CooperSurgical focuses on women's healthcare, providing medical devices, fertility treatments, and genomic products. It acts as a complementary, steady-growth segment that diversifies the company's overall revenue base.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.